Exciting work also explores the prospect of utilizing bioengineered, recombinant bacteria as treatment for hypertension: a recent study reported that Lactobacillus modified to express human ACE2 (hACE2) lowers BP in female, but not male, hypertensive Ace2–/– Dahl salt-sensitive rats (144). The gene discussed is ACE2; the disease is hypertensive disorder.